Anxiolytics

YOUTH EXPOSED HUNDREDS OF MILLIONS OF TIMES TO NONCOMPLIANT ALCOHOL ADS ON CABLE TV

Retrieved on: 
Friday, June 19, 2020

With support from the Centers for Disease Control and Prevention (CDC), the Abt/Boston University team is monitoring total and noncompliant youth exposure to alcohol ads on cable TV.

Key Points: 
  • With support from the Centers for Disease Control and Prevention (CDC), the Abt/Boston University team is monitoring total and noncompliant youth exposure to alcohol ads on cable TV.
  • The study found that:
    Total youth exposure to alcohol ads on cable TV decreased by 16 percent, and noncompliant exposure decreased by 26 percent.
  • The 25 alcohol brands with the most noncompliant alcohol ad exposure were responsible for 71 percent of all noncompliant ads.
  • By monitoring alcohol ads on cable TV, we can help hold the alcohol industry accountable to its guidelines designed to prevent adolescent alcohol use.

Global Food Grade Alcohol Market Opportunity Assessment 2019-2029 - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 18, 2020

Global Food Grade Alcohol Market Demand (Size in US$ Mn) Analysis 2014-2018 and Forecast, 2019-2028

Key Points: 
  • Global Food Grade Alcohol Market Demand (Size in US$ Mn) Analysis 2014-2018 and Forecast, 2019-2028
    9.1.
  • Global Food Grade Alcohol Market Analysis 2014-2018 and Forecast, 2019-2028, By Product Type
    10.2.
  • Global Food Grade Alcohol Market Analysis 2014-2018 and Forecast, 2019-2028, By Application
    11.2.
  • Global Food Grade Alcohol Market Analysis 2014-2018 and Forecast, 2019-2028, By Region
    12.2.

Alprazolam Market 2020-2024 | Increasing Prevalence of Anxiety Disorders to Boost Growth | Technavio

Retrieved on: 
Saturday, June 13, 2020

The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Key Points: 
  • The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.
  • View the full release here: https://www.businesswire.com/news/home/20200612005499/en/
    Technavio has announced its latest market research report titled Global Alprazolam Market 2020-2024 (Graphic: Business Wire)
    Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19.
  • Market estimates include pre- and post-COVID-19 impact on the Alprazolam Market Download free sample report
    The market is fragmented, and the degree of fragmentation will accelerate during the forecast period.
  • The increasing prevalence of anxiety disorders has been instrumental in driving the growth of the market.

TBRC COVID-Impact Report Insights: Growing Demand For Ethyl Alcohol-based Sanitizers

Retrieved on: 
Tuesday, June 9, 2020

Read More On The Business Research Company's Ethyl Alcohol Manufacturing Market Report:

Key Points: 
  • Read More On The Business Research Company's Ethyl Alcohol Manufacturing Market Report:
    Rising demand for ethanol in the food processing industry is also contributing to the growth of the ethyl alcohol market.
  • The demand for ethanol in the food processing industry will lead to the expansion of the global market for ethyl alcohol.
  • Rising demand for ethanol in the food processing industry is expected to boost the demand for ethyl alcohol during the forecast period, thus driving market growth.
  • Request A Free Sample Of The Ethyl Alcohol Manufacturing Market Report:
    The ethyl alcohol market consists of sales of ethyl alcohol and related services.

UCB Acquires Engage Therapeutics: Staccato® Alprazolam - A potential Solution for Acute On-demand Seizure Management for People Living With Epilepsy

Retrieved on: 
Friday, June 5, 2020

Charl van Zyl, Executive Vice President UCB and Head of Neurology said: "Like UCB, Engage is a company with a deep-seated passion in epilepsy.

Key Points: 
  • Charl van Zyl, Executive Vice President UCB and Head of Neurology said: "Like UCB, Engage is a company with a deep-seated passion in epilepsy.
  • Staccato Alprazolam is an excellent strategic fit with our patient value growth strategy in epilepsy.
  • The Staccato system rapidly vaporizes alprazolam to form an aerosol, with particle size designed for deep lung delivery to produce a rapid, systemic effect.
  • Engage acquired worldwide rights to Staccato Alprazolam in 2017 under a license agreement with Alexza Pharmaceuticals Inc., Mountain View, CA, U.S.

UCB Acquires Engage Therapeutics: Staccato® Alprazolam - A potential Solution for Acute On-demand Seizure Management for People Living With Epilepsy

Retrieved on: 
Friday, June 5, 2020

License and supply agreements in place with Alexza Pharmaceuticals, Inc., the inventor, licensor and manufacturer of Staccato Alprazolam.

Key Points: 
  • License and supply agreements in place with Alexza Pharmaceuticals, Inc., the inventor, licensor and manufacturer of Staccato Alprazolam.
  • Charl van Zyl, Executive Vice President UCB and Head of Neurology said: "Like UCB, Engage is a company with a deep-seated passion in epilepsy.
  • Staccato Alprazolam is an excellent strategic fit with our patient value growth strategy in epilepsy.
  • Engage acquired worldwide rights to Staccato Alprazolam in 2017 under a license agreement with Alexza Pharmaceuticals Inc., Mountain View, CA, U.S.

Tonix Pharmaceuticals Posted Results from Pharmacokinetic Analyses of TNX-102 SL and TNX-601 CR in Advance of Virtual Poster Presentations at the American Society of Clinical Psychopharmacology

Retrieved on: 
Thursday, May 21, 2020

Dr. Sullivan continued, Based on the PK results of the TNX-601 CR study, TNX-601 CR 39.4 mg demonstrated PK appropriate for once-daily dosing with minimal food effect.

Key Points: 
  • Dr. Sullivan continued, Based on the PK results of the TNX-601 CR study, TNX-601 CR 39.4 mg demonstrated PK appropriate for once-daily dosing with minimal food effect.
  • We believe these findings support further development of TNX-601 CR, the once-daily formulation of tianeptine, in MDD, PTSD and corticosteroid-induced cognitive dysfunction.
  • Tonixs current portfolio includes biologics to prevent infectious diseases, and small molecules and biologics to treat pain, psychiatric and addiction conditions.
  • Tonixs most advanced product candidate, TNX-102 SL**, is in Phase 3 development as a bedtime treatment for fibromyalgia and PTSD.

Neurelis Announces Total Of Nine Poster Presentations For The AANN, AMCP, And AAN Annual Meetings

Retrieved on: 
Wednesday, May 20, 2020

The posters are all available for review online due to the cancellation of the organizations' annual meetings because of the COVID-19 pandemic.

Key Points: 
  • The posters are all available for review online due to the cancellation of the organizations' annual meetings because of the COVID-19 pandemic.
  • Neurelis Chief Medical Officer Enrique Carrazana, M.D., said the poster presentations continue to validate the safety, pharmacokinetic, and tolerability of VALTOCO (diazepam nasal spray).
  • These presentations have been made possible by the participation of our investigators, their dedicated staffand, most significantly, the patients who participated in these important studies."
  • In a long-term, open-label, repeat-dose clinical trial, the safety of VALTOCO was evaluated and more than 4,000 seizures were treated.

Impact of COVID-19 on the Worldwide Alcoholic Beverages Industry to 2030 - Featuring Anheuser Busch InBev, Heineken & Diageo Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, May 18, 2020

The "Alcoholic - Beverages Global Market Report 2020-30: COVID- 19 Impact and Recovery" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Alcoholic - Beverages Global Market Report 2020-30: COVID- 19 Impact and Recovery" report has been added to ResearchAndMarkets.com's offering.
  • The low growth is mainly due to economic slowdown across countries owing to the COVID-19 outbreak and the measures to contain it.
  • The alcoholic beverages market consists of sales of alcoholic beverages by entities (organizations, sole traders and partnerships) that produce alcoholic beverages through the fermentation process and that produce distilled alcoholic beverages.
  • The companies in the alcoholic beverages industry process raw materials into alcoholic beverages, package and distribute them through various distribution channels to both individual customers and commercial establishments.

Xeris Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Updates

Retrieved on: 
Thursday, May 7, 2020

Results showed that a mini-dose of RTU glucagon was adequate to maintain normal blood glucose levels during prolonged, moderate-to-intense aerobic exercise.

Key Points: 
  • Results showed that a mini-dose of RTU glucagon was adequate to maintain normal blood glucose levels during prolonged, moderate-to-intense aerobic exercise.
  • The blinded out-patient stage, where subjects will be exercising on their own at home, is currently ongoing with results expected in the second quarter of 2020.
  • Results showed that Xeris intramuscular (IM) diazepam maintains higher concentration over a longer time period versus standard of care.
  • Xeris Pharmaceuticals will host a conference call and webcast today, Thursday, May 7, 2020 at 8:30 a.m. Eastern Time.